查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1696208

全球多组学市场 - 2025 至 2033 年

Global Multi-omics Market - 2025-2033
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

2024 年全球多组学市场规模达到 32.5 亿美元，预计到 2033 年将达到 332.5 亿美元，2025-2033 年预测期内的复合年增长率为 26.1%。

多组学是一种整合各种组学技术的多学科方法，透过分析来自各个分子层的资料来帮助发现生物标誌物，了解疾病机制并推进个人化医疗。

由于精准医疗的采用、药物发现研究和定序技术，全球多组学市场正经历显着成长。关键驱动因素包括对综合生物资料分析、政府资助以及医疗保健和生物技术应用的需求。北美凭藉着强大的研究基础设施引领市场，而亚太地区正成为一个利润丰厚的地区。赛默飞世尔科技、Illumina 和 QIAGEN 等主要参与者正在推动该领域的创新。

市场动态：

驱动因素与约束因素

精准医疗的应用日益广泛

全球多组学市场受到精准医疗日益增长的关注所推动，精准医疗可以让人们更深入地了解个人基因、蛋白质体学和代谢特征。政府和医疗保健组织正在大力投资多组学研究，以开发针对癌症和神经系统疾病等复杂疾病的个人化治疗方法。人工智慧与生物资讯学的融合加速了药物发现和针对患者的治疗策略。

例如，2025 年 1 月，3D 基因组学技术的先驱 Enhanc3D Genomics 推出了一套整合的多组学解决方案，以提高药物发现的精确度。该解决方案基于该公司专有的3D基因组学平台，为合作伙伴提供全面的端到端解决方案，以支援整个药物发现和开发过程的决策。

数据复杂性与集成

全球多组学市场因资料复杂性和整合性而面临挑战，因为它从基因组学、转录组学、蛋白质组学和代谢组学产生了大量异质资料。这需要先进的计算工具来进行有意义的解释、跨平台的标准化以及资料库之间的互通性。确保资料的准确性、可重复性和可扩展性需要高效能运算和复杂的演算法，这限制了小型研究组织和临床应用的可近性。

目录

第一章：市场介绍和范围

  • 报告目标
  • 报告范围和定义
  • 报告范围

第 2 章：高阶主管见解与关键要点

  • 市场亮点和战略要点
  • 主要趋势和未来预测
  • 按产品和服务分类的摘要
  • 技术片段
  • 按应用程式截取的程式码片段
  • 最终用户的程式码片段
  • 按地区分类的片段

第 3 章：动态

  • 影响因素
    • 驱动程式
      • 精准医疗的应用日益广泛
      • 定序技术的进步
    • 限制
      • 数据复杂性与集成
      • 监管和道德问题
    • 机会
      • 基于云端的多组学解决方案的开发
    • 影响分析

第四章：战略洞察与产业展望

  • 市场领导者和先驱者
    • 新兴先锋和杰出参与者
    • 拥有最大、最畅销品牌的成熟领导者
    • 拥有成熟产品的市场领导者
  • CXO 观点
  • 最新进展与突破
  • 案例研究/正在进行的研究
  • 监管和报销情况
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲
  • 波特五力分析
  • 供应链分析
  • 专利分析
  • SWOT 分析
  • 未满足的需求和差距
  • 市场进入和扩张的推荐策略
  • 情境分析：最佳情况、基本情况和最坏情况预测
  • 定价分析和价格动态
  • 关键意见领袖

第 5 章：按产品和服务

  • 仪器
  • 耗材和试剂
  • 服务

第 6 章：按技术

  • 基因组学
  • 转录组学
  • 蛋白质体学
  • 代谢组学
  • 表观基因组学

第 7 章：按应用

  • 药物研发
  • 精准医疗
  • 临床诊断
  • 生物技术与工业应用

第 8 章：按最终用户

  • 製药及生技公司
  • 研究机构和学术中心
  • 医院和诊所
  • CRO 和 CDMO

第九章：区域市场分析与成长机会

  • 北美洲
    • 各区域关键动态
      • 我们
      • 加拿大
  • 欧洲
    • 各区域关键动态
      • 德国
      • 英国
      • 法国
      • 西班牙
      • 义大利
      • 欧洲其他地区
  • 拉丁美洲
    • 各区域关键动态
      • 墨西哥
      • 巴西
      • 阿根廷
      • 拉丁美洲其他地区
  • 亚太
    • 各区域关键动态
      • 中国
      • 印度
      • 日本
      • 韩国
      • 亚太其他地区
  • 中东和非洲
    • 各区域关键动态

第 10 章：竞争格局与市场定位

  • 竞争概况和主要市场参与者
  • 市占率分析与定位矩阵
  • 策略伙伴关係、併购
  • 产品组合和创新的关键发展
  • 公司基准化分析

第 11 章：公司简介

  • BD (Becton, Dickinson and Company)
    • 公司概况
    • 产品组合
      • 产品描述
      • 产品关键绩效指标 (KPI)
      • 历史和预测产品销售量
      • 产品销售量
    • 财务概览
      • 公司收入
      • 地区收入份额
      • 收入预测
    • 关键进展
      • 合併与收购
      • 关键产品开发活动
      • 监管部门批准等
    • SWOT 分析
  • Thermo Fisher Scientific Inc
  • Illumina, Inc
  • Danaher Corporation
  • Bruker Corporation
  • QIAGEN NV
  • Agilent Technologies, Inc
  • Genedata
  • Shimadzu Corporation
  • Element Biosciences

第 12 章：假设与研究方法

  • 资料收集方法
  • 数据三角测量
  • 预测技术
  • 数据验证和确认

第 13 章：附录

简介目录
Product Code: BT7715

The global multi-omics market reached US$ 3.25 Billion in 2024 and is expected to reach US$ 33.25 Billion by 2033, growing at a CAGR of 26.1% during the forecast period 2025-2033.

Multiomics is a multidisciplinary approach that integrates various omics technologies, aiding in the discovery of biomarkers, understanding disease mechanisms, and advancing personalized medicine by analyzing data from various molecular layers.

The global multiomics market is experiencing significant growth due to precision medicine adoption, drug discovery research, and sequencing technologies. Key drivers include demand for integrated biological data analysis, government funding, and healthcare and biotechnology applications. North America leads the market due to strong research infrastructure, while Asia-Pacific is emerging as a lucrative region. Major players like Thermo Fisher Scientific, Illumina, and QIAGEN are driving innovation in this field.

Market Dynamics: Drivers & Restraints

Rising Adoption of Precision Medicine

The global multiomics market is driven by the growing focus on precision medicine, which allows for a deeper understanding of individual genetic, proteomic, and metabolic profiles. Governments and healthcare organizations are investing heavily in multiomics research to develop personalized therapies for complex diseases like cancer and neurological disorders. The integration of artificial intelligence and bioinformatics accelerates drug discovery and patient-specific treatment strategies.

For instance, in January 2025, Enhanc3D Genomics, a pioneer in 3D genomics technology, launched a suite of integrated multi-omics solutions to enhance drug discovery precision. The solutions, based on the company's proprietary 3D genomics platform, provide partners with a comprehensive end-to-end solution to support decision-making throughout the drug discovery and development process.

Data Complexity and Integration

The global multiomics market faces challenges due to data complexity and integration, as it generates vast heterogeneous data from genomics, transcriptomics, proteomics, and metabolomics. This requires advanced computational tools for meaningful interpretation, standardization across platforms, and interoperability between databases. Ensuring data accuracy, reproducibility, and scalability requires high-performance computing and sophisticated algorithms, which limits accessibility for smaller research organizations and clinical applications.

Segment Analysis

The global multi-omics market is segmented based on product & service, technology, application, end-user, and region.

Product & Service:

The instruments from the product & service segment are expected to dominate the multi-omics market with the highest market share.

Multiomics instruments, including NGS platforms, mass spectrometers, and microarrays, are specialized lab equipment used in various omics fields for precise detection, quantification, and characterization of biological molecules, enabling high-throughput data generation and drug development.

Instruments are vital in the global multiomics market, enabling precise analysis of biological molecules in genomics, transcriptomics, proteomics, and metabolomics. Advanced sequencing platforms, mass spectrometers, chromatography systems, and imaging technologies generate high-resolution data, facilitating molecular profiling, biomarker discovery, and disease mechanism studies. Continuous innovations in automation, miniaturization, and high-throughput analysis improve efficiency and accessibility, making multiomics technologies more accessible for research institutes, biotechnology companies, and clinical laboratories.

For instance, in June 2024, Mission Bio launched the Tapestri Single-cell Multiple Myeloma Multiomics Solution, a product suite designed to revolutionize multiple myeloma research and therapeutic development. The suite offers comprehensive insights into disease evolution and biology at the single-cell level, enabling researchers and drug developers to understand therapy resistance and disease relapse at the subclonal level. This new product suite will enhance the understanding of disease progression and treatment resistance.

Geographical Analysis

North America is expected to hold a significant position in the multi-omics market with the highest market share

North America leads the global multi-omics market due to its significant product launches, robust research infrastructure, government funding, and key industry players. The region's biotechnology and pharmaceutical sectors invest in multi-omics technologies for drug discovery, precision medicine, and clinical diagnostics. Advanced sequencing platforms, bioinformatics tools, and AI-driven analytics enhance research capabilities.

For instance, in September 2024, The Translational Genomics Research Institute (TGen), part of the City of Hope, launched the Center for Spatial Multi-Omics (COSMO), a service center aimed at transforming biomedical research through spatial biology. COSMO offers services to visualize and map molecular data at the single-cell level within tissues, preserving important cellular environments and structures for histological analysis. Advanced technologies enable researchers to examine thousands of RNA targets in detail.

Moreover, partnerships and collaborations between academic institutions and biotech firms accelerate innovation which indeed helps the region to grow during the forecast period. For instance, in January 2024, Thermo Fisher Scientific Inc. and Akoya Biosciences signed a license and distribution agreement to provide a comprehensive solution for spatial multi-omics workflows, simplifying the whole-slide, multi-omics imaging process and examining protein and RNA, crucial for cancer research fields.

Furthermore, in January 2024, BD partnered with Hamilton Company to create robotics-compatible and automated reagent kits for large-scale single-cell multi-omics experiments, aiming to standardize and minimize human error.

Competitive Landscape

The major global players in the multi-omics market include BD (Becton, Dickinson, and Company), Thermo Fisher Scientific Inc., Illumina, Inc., Danaher Corporation, Bruker Corporation, QIAGEN N.V, Agilent Technologies, Inc., Genedata, Shimadzu Corporation, and Element Biosciences among others.

Key Developments

  • In May 2024, QIAGEN launched its QIAseq Multimodal DNA/RNA Library Kit, which enables the preparation of DNA and RNA libraries for next-generation sequencing, including whole genome sequencing and whole transcriptome sequencing, and downstream target enrichment using hybrid-capture from a single sample.
  • In June 2023, Singleton, a trusted partner for scientists and clinicians, launched two new single-cell multi-omics products: NEO and Python Junior. These portable instruments are designed to fit into any laboratory and deliver accurate and reproducible results. The NEO library processing system and Python Junior tissue dissociation instrument aim to make single-cell sequencing accessible for every laboratory, ensuring accurate and reproducible results for researchers and clinicians alike.

Why Purchase the Report?

  • Technological Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global multi-omics market report delivers a detailed analysis with 70 key tables, more than 65 visually impactful figures and 159 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Application & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Product & Service
  • 2.4. Snippet by Technology
  • 2.5. Snippet by Application
  • 2.6. Snippet by End-User
  • 2.7. Snippet by Region

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Rising Adoption of Precision Medicine
      • 3.1.1.2. Advancements in Sequencing Technologies
    • 3.1.2. Restraints
      • 3.1.2.1. Data Complexity and Integration
      • 3.1.2.2. Regulatory and Ethical Concerns
    • 3.1.3. Opportunity
      • 3.1.3.1. Development of Cloud-Based Multi-omics Solutions
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established leaders with largest largest-selling Brand
    • 4.1.3. Market leaders with established Product
  • 4.2. CXO Perspectives
  • 4.3. Latest Developments and Breakthroughs
  • 4.4. Case Studies/Ongoing Research
  • 4.5. Regulatory and Reimbursement Landscape
    • 4.5.1. North America
    • 4.5.2. Europe
    • 4.5.3. Asia Pacific
    • 4.5.4. Latin America
    • 4.5.5. Middle East & Africa
  • 4.6. Porter's Five Force Analysis
  • 4.7. Supply Chain Analysis
  • 4.8. Patent Analysis
  • 4.9. SWOT Analysis
  • 4.10. Unmet Needs and Gaps
  • 4.11. Recommended Strategies for Market Entry and Expansion
  • 4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.13. Pricing Analysis and Price Dynamics
  • 4.14. Key Opinion Leaders

5. By Product & Service

  • 5.1. Introduction
    • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product & Service
    • 5.1.2. Market Attractiveness Index, By Product & Service
  • 5.2. Instruments*
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 5.3. Consumables & Reagents
  • 5.4. Services

6. By Technology

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 6.1.2. Market Attractiveness Index, By Technology
  • 6.2. Genomics*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Transcriptomics
  • 6.4. Proteomics
  • 6.5. Metabolomics
  • 6.6. Epigenomics

7. By Application

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 7.1.2. Market Attractiveness Index, By Application
  • 7.2. Drug Discovery & Development*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Precision Medicine
  • 7.4. Clinical Diagnostics
  • 7.5. Biotechnology & Industrial Applications

8. By End-User

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.1.2. Market Attractiveness Index, By End-User
  • 8.2. Pharmaceutical & Biotechnology Companies*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Research Institutes & Academic Centers
  • 8.4. Hospitals & Clinics
  • 8.5. CROs & CDMOs

9. Regional Market Analysis and Growth Opportunities

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product & Service
    • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.2.7.1. U.S.
      • 9.2.7.2. Canada
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product & Service
    • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.3.7.1. Germany
      • 9.3.7.2. U.K.
      • 9.3.7.3. France
      • 9.3.7.4. Spain
      • 9.3.7.5. Italy
      • 9.3.7.6. Rest of Europe
  • 9.4. Latin America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product & Service
    • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.4.7.1. Mexico
      • 9.4.7.2. Brazil
      • 9.4.7.3. Argentina
      • 9.4.7.4. Rest of Latin America
  • 9.5. Asia-Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product & Service
    • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.5.7.1. China
      • 9.5.7.2. India
      • 9.5.7.3. Japan
      • 9.5.7.4. South Korea
      • 9.5.7.5. Rest of Asia-Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product & Service
    • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

10. Competitive Landscape and Market Positioning

  • 10.1. Competitive Overview and Key Market Players
  • 10.2. Market Share Analysis and Positioning Matrix
  • 10.3. Strategic Partnerships, Mergers & Acquisitions
  • 10.4. Key Developments in Product Portfolios and Innovations
  • 10.5. Company Benchmarking

11. Company Profiles

  • 11.1. BD (Becton, Dickinson and Company) *
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio
      • 11.1.2.1. Product Description
      • 11.1.2.2. Product Key Performance Indicators (KPIs)
      • 11.1.2.3. Historic and Forecasted Product Sales
      • 11.1.2.4. Product Sales Volume
    • 11.1.3. Financial Overview
      • 11.1.3.1. Company Revenue's
      • 11.1.3.2. Geographical Revenue Shares
      • 11.1.3.3. Revenue Forecasts
    • 11.1.4. Key Developments
      • 11.1.4.1. Mergers & Acquisitions
      • 11.1.4.2. Key Product Development Activities
      • 11.1.4.3. Regulatory Approvals, etc.
    • 11.1.5. SWOT Analysis
  • 11.2. Thermo Fisher Scientific Inc
  • 11.3. Illumina, Inc
  • 11.4. Danaher Corporation
  • 11.5. Bruker Corporation
  • 11.6. QIAGEN N.V
  • 11.7. Agilent Technologies, Inc
  • 11.8. Genedata
  • 11.9. Shimadzu Corporation
  • 11.10. Element Biosciences

LIST NOT EXHAUSTIVE

12. Assumption and Research Methodology

  • 12.1. Data Collection Methods
  • 12.2. Data Triangulation
  • 12.3. Forecasting Techniques
  • 12.4. Data Verification and Validation

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us